Pfizer, Actavis settle Celebrex patent litigation
This article was originally published in Scrip
Executive Summary
A week after Pfizer settled patent litigation with Israeli drug maker Teva over Celebrex (celecoxib), the New York giant has entered into an agreement with Actavis, clearing the way for that firm, too, to market a copycat version of the drug at the 50mg, 100mg, 200mg and 400mg doses.